Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis
Canadian Journal of Gastroenterology and Hepatology · 2021-01 · 2021 (1)
DOI: 10.1155/2021/6691425 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Canadian Journal of Gastroenterology and Hepatology, online erschienen am 21.01.2021. Verfasst von Xinyu Xiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hos…. Hauptthemen laut MEDLINE: Cholangitis, Liver Cirrhosis, Biliary. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: West China Hospital, Sichuan University.
Abstract (Originalsprache)
Aim
To compare the response between the current recommended dosage 13–15 mg/kg/d and 20 mg/kg/d dose of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) patients who do not respond completely to a standard dose of UDCA.
Methods
We included 73 patients with poor response and randomized them into two groups to investigate whether increasing the dosage of UDCA was beneficial to nonresponders. Patients assigned to the 13–15 mg/kg/d group continued with standard therapy, and participants in the 18–22 mg/kg/d group switched to the higher dosage (18–22 mg/kg/d), with a follow‐up of 12 months for both groups. The primary endpoints were the rate of response at 6 months and drug side effects.
Results
According to the Paris 2 criteria, patients receiving 18–22 mg/kg/d UDCA achieved a response rate of 59.4% compared with 36.1% in the standard dosage group ( P = 0.046) at 6 months, respectively. At 12 months, the high‐UDCA‐dosage group achieved a response rate of 59.4% compared with 47.2% in the standard dosage group ( P = 0.295), respectively. Additionally, the risk score predicted by the UK‐PBC model was lower in high‐dosage UDCA‐treated patients than in the standard dosage group (all P < 0.05). Side effects include diarrhea, nausea and vomiting, rash, and newly developed high blood pressure, which were mild and tolerated.
Conclusions
Patients treated with the high UDCA dosage showed some advantages over those who continued the standard dosage in terms of biochemical remission and disease progression, indicating that standard therapy with UDCA for 6 months and then another 1 year with high UDCA dosage for nonresponders could be a treatment option before second‐line therapy is recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu, China.
- Department of Gastroenterology & Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
ORCID-Profile: Xiaoli Fan, Li Yang
Förderung
- West China Hospital, Sichuan University
Zitieren
APA
Xiang, X., Yang, X., Shen, M., Huang, C., Liu, Y., Fan, X., & Yang, L. (2021). Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis. Canadian Journal of Gastroenterology and Hepatology, 2021(1). https://doi.org/10.1155/2021/6691425
Vancouver
Xiang X, Yang X, Shen M, Huang C, Liu Y, Fan X, et al. Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis. Canadian Journal of Gastroenterology and Hepatology. 2021;2021(1). doi:10.1155/2021/6691425
BibTeX
@article{Xiang2021,
author = {Xiang, Xinyu and Yang, Xiaoli and Shen, Mengyi and Huang, Chen and Liu, Yifeng and Fan, Xiaoli and Yang, Li},
title = {Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis},
journal = {Canadian Journal of Gastroenterology and Hepatology},
year = {2021},
volume = {2021},
number = {1},
doi = {10.1155/2021/6691425}
}
EUVIMED